CAS: 315-37-7; Testosterone Enanthate

上下游产品

testosterone Heptanoic acid chloride 3-ethoxyandrosta-3,5-dien-17-one 17β-hydroxy-3-ethoxyandrosta-3,5-diene3-oxo-5α-androstan-17β-yl heptanoate testosterone Androstenedione 6β-hydroxytestosterone

3-乙氧基-雄甾-3,5-二烯-17-酮置于吡啶,盐酸,4-二甲氨基吡啶,钾硼氢,盐酸-N-乙基-N'-(3-二甲氨基丙基)碳二亚胺体系中,用 四氢呋喃,乙醇,水,1,2-二氯乙烷 用作溶剂,化学反应生成庚酸睾酮
参考文献:一种烷基酸睾酮的合成方法
标题:一种烷基酸睾酮的合成方法
摘要:本发明公开了一种烷基酸睾酮的合成方法,属于药物的合成加工技术领域.该方法以4‑雄烯二酮(4Ad)为起始原料,先3位酮基进行烯醇醚保护,然后17位羰基还原成羟基,经酯化和3位水解得到睾酮酯化物,或者以4‑雄烯二酮(4Ad)为起始原料,先3位酮基进行烯醇醚保护,然后17位羰基还原成羟基,再3位水解得到睾丸素,睾丸素3位缩酮保护后,经酯化和3位水解得到睾酮酯化物.本发明方法中酯化反应时3位被保护,可以减少杂质产生,酯化反应溶剂为一种与水不溶的有机溶剂,因此反应完成后,可直接分层提取产物,不需加入大量水析出产物,减少了废水的量,而且溶剂可以回收利用,使工艺更符合工业化生产.

专利信息

专利号:US-7759520-B2
优先权日:1996-11-27
标 题 :Synthesis of selective androgen receptor modulators
发明人：DALTON JAMES T; MILLER DUANE D; YIN DONGHUA; HE YALI
权利人:UNIV TENNESSEE RES FOUNDATION
摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

专利号:US-6995284-B2
优先权日:2000-08-24
标题 :Synthesis of selective androgen receptor modulators
发明人：DALTON JAMES T; MILLER DUANE D; HE YALI; YIN DONGHUA
权利人:UNIV TENNESSEE RES FOUNDATION
摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:US-7968721-B2
优先权日:2003-01-13
标 题:Large-scale synthesis of selective androgen receptor modulators
发明人：MILLER DUANE D; VEVERKA KAREN A; CHUNG KIWON
权利人:UNIV TENNESSEE RES FOUNDATION
摘要:This invention relates to a process for preparing a selective androgen receptor modulator (SARM) compound represented by the structure of formula I: n nwherein X is O; and T, Z, Y, Q, R and R 1 are defined herein. The process includes coupling between an amide of formula II and a phenol of formula IIIn n n n n n n n n n n nfollowed by a purification step consisting of precipitating the compound of formula (I) in a mixture of alcohol and water alone.

专利号:US-12295961-B2
优先权日:2009-12-31
标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
发明人：DHINGRA OM
权利人:MARIUS PHARMACEUTICALS INC
摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

专利号:US-6274582-B1
优先权日:1997-02-24
标题 :Preparation for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
发明人：MAARIN PER
权利人:CORTENDO AB
摘要:Human growth hormone is used in combination with a cortisol synthesis inhibitor, in particular ketoconazole, for prevention or treatment of conditions related to Metabolis Syndrome (Neuroendocrine Syndrome). Administration can be supplemented by a sex hormone selected from testosterone and natural or synthetic estrogen. Also disclosed are corresponding pharmaceutical compositions.